- $88.40m
- -$4.45m
- $0.86m
Brief: Rallybio Announces Collaboration To Advance Therapeutic Solutions For Pregnant Individuals At Risk Of Fetal And Neonatal Alloimmune Thrombocytopenia
U.S. RESEARCH ROUNDUP-Ashland, Oportun Financial, Palomar Holdings
Brief: Rallybio Q4 Net Income USD -20.242 Million
U.S. STOCKS ON THE MOVE-Adobe, United Parcel Service, ZeroFox Holdings
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Rallybio, Willis Towers Watson
Rallybio rises as co announces job cuts
Brief: Rallybio Announces Portfolio Prioritization And Provides Corporate Update
Brief: Rallybio Corp Phase 2 Study For Rlyb212 Expected To Initiate In 2H 2024
Brief: Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data For Rlyb116
Brief: Rallybio Presents Natural History Study For Fetal And Neonatal Alloimmune Thrombocytopenia
Brief: Rallybio Announces Preliminary Multiple Dose Data From The Completed Phase 1 Safety And Pharmacokinetics Study For RLYB212
Brief: Rallybio Q3 Net Income USD -18.374 Million
Brief: Rallybio Reports Second Quarter 2023 Financial Results
Brief: Rallybio Q2 Net Income USD -18.63 Million
Brief: Rallybio Appoints Stephen Uden As CEO
Brief: Rallybio Announces Proof-Of-Concept Results And Development Updates For Rlyb212, A Novel Monoclonal Anti-HPA-1A Antibody
Brief: Rallybio Corp Files For Offering Of Up To 12.35 Mln Shares By Selling Stockholders - SEC Filing
Brief: Rallybio Reports Q1 2023 Financial Results
Brief: Rallybio Q1 basic EPS of USD -0.43